Complete Genomics will share details of various multi-omics and spatial transcriptomics applications based on its sequencing technology at the 2024 American Society of Human Genetics (ASHG) Meeting. Several customers will also present case studies that highlight the benefits of the company’s technology at the meeting.
According to the company, its flagship sequencer, DNBSEQ-T7, has gained more adoption in the market within the last year, for sequencing DNA, RNA, and protein data. The DNBSEQ-T7 platform is capable of generating up to 7 Tb of data per day, with a maximum read length of 150 bp paired-end reads and an accuracy rate of more than 99.9%.
In addition to showcasing the DNBSEQ-T7 during ASHG, Complete Genomics will discuss its expanded portfolio of sequencing solutions for whole-genome sequencing, spatial transcriptomics, proteomics, and single-cell sequencing. They will also discuss CompleteWGS, a comprehensive workflow solution that leverages the DNBSEQ sequencing technology. It provides increased genomic coverage, improved sequencing of challenging genes, and haplotype phasing.
Sequencing solutions
Complete Genomics will be showcasing its DNBSEQ-G400RS FluoXpert instrument, a multifunctional sequencer that merges high-throughput sequencing with multiplex immunofluorescence (mIF). The solution is designed to support in vivo spatial protein detection and multi-omics analysis for both DNA/RNA and protein data in a single system.
Attendees can also learn about the DNBSEQ-G800 benchtop sequencer, which is intended to provide greater accuracy and longer, single-end reads of 600 bp and beyond. According to the company, the solution provides the longest single reads among short-read sequencers. It also features the CoolMPS technology, which the company claims offers improved variant calling for various applications. The solution is ideal for sequencing highly variable or repetitive genomic regions, identifying structural variants, full-length transcriptome RNA-sequencing, and more.
The company will also highlight its fully automated DNBelab-D4 digital sample preparation system for preparing libraries from DNA or RNA samples to DNA Nanoballs in about 2.5–3.5 hours. Complete Genomics is marketing the solution for metagenomics, targeted sequencing, whole genome sequencing, and converting third-party libraries for DNBSEQ compatibility.
Lastly, the company will present the DNBSEQ-G99, which it claims can deliver Q40 data quality for various sequencing applications. It offers two independent flow cells for up to 48 Gb in less than 12 hours for PE150 (from loading to FASTQ), or 96 Gb in 30 hours for PE300.
Separately, the company has taken steps to beef up its data analysis capabilities. Last month, it announced that it would be integrating the DNBSEQ platforms with NVIDIA’s Parabricks software for secondary analysis. In addition to supporting a wider range of sequencing data formats, including those specific to DNBSEQ, Parabricks offers updated versions of popular variant calling tools, such as the Genome Analysis ToolKit and DeepVariant, that have been optimized for GPU acceleration. These tools offer improved sensitivity and specificity, making them well-suited for identifying low-frequency variants.
Other updates
Complete Genomics also announced that it will be the exclusive distributor of STOmics products in the United States. Established in 2020, STOmics offers an unbiased, high-resolution spatiotemporal multi-omics platform that is powered by the Stereo-seq technology. As part of the agreement, Complete Genomics is also launching a grant program for researchers who want to incorporate spatial transcriptomics into their research.
The so-called Spatial Xcellerator grant program will provide access to advanced spatial transcriptomics technologies for studying gene expression at single-cell resolution. Through the program, the company is offering free reagents and sequencing as well as training and support from sample preparation to data analysis. Researchers will be able to use the company’s specialized solutions for large-chip and formalin-fixed paraffin-embedded samples. Interested researchers in the United States can apply to two targeted tracks—cancer research and tissue atlas studies.
To receive more ASHG news from GEN, including on-the-ground reporting, register for our newsletter here.
